These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
613 related items for PubMed ID: 18793860
1. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP. Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860 [Abstract] [Full Text] [Related]
3. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M. Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091 [Abstract] [Full Text] [Related]
4. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, Hill HR, Fire E, Spector L, Yarden J, Dotan N, Rose JW. J Neuroimmunol; 2009 Dec 10; 217(1-2):95-101. PubMed ID: 19879655 [Abstract] [Full Text] [Related]
8. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D. Neurology; 2011 Jan 04; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [Abstract] [Full Text] [Related]
12. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. Madia F, Frisullo G, Nociti V, Conte A, Luigetti M, Del Grande A, Patanella AK, Iorio R, Tonali PA, Batocchi AP, Sabatelli M. J Peripher Nerv Syst; 2009 Jun 04; 14(2):107-17. PubMed ID: 19691533 [Abstract] [Full Text] [Related]
13. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication. Festoff BW, Li C, Woodhams B, Lynch S. J Neurol Sci; 2012 Dec 15; 323(1-2):61-5. PubMed ID: 22967748 [Abstract] [Full Text] [Related]
14. Gray matter atrophy in multiple sclerosis: a longitudinal study. Fisher E, Lee JC, Nakamura K, Rudick RA. Ann Neurol; 2008 Sep 15; 64(3):255-65. PubMed ID: 18661561 [Abstract] [Full Text] [Related]
18. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Hamamcioglu K, Reder AT. Mult Scler; 2007 May 15; 13(4):459-70. PubMed ID: 17463069 [Abstract] [Full Text] [Related]
19. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D. Mult Scler; 2012 Aug 15; 18(8):1092-8. PubMed ID: 22695538 [Abstract] [Full Text] [Related]
20. Multislice brain myelin water fractions at 3T in multiple sclerosis. Oh J, Han ET, Lee MC, Nelson SJ, Pelletier D. J Neuroimaging; 2007 Apr 15; 17(2):156-63. PubMed ID: 17441837 [Abstract] [Full Text] [Related] Page: [Next] [New Search]